Title
Category
Credits
Event date
Cost
Breaking the Cycle in Cardiorenal Anemia Syndrome: The Practice-changing Role of IV Iron at the CKD–Heart Failure Interface
  • Cardiology
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies. The vicious cycle of cardiorenal anemia syndrome (CRAS)—the pathologic triad wherein the three conditions are each capable of causing and/or being caused by the other—can be effectively mitigated and managed with IV iron.
Navigating Novel Terrain in Anemia of Chronic Kidney Disease: A Patient-centric Review of Disease State, Current Chasms in Care, and the Future Promise of HIF-PH Inhibition
  • Nephrology
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should be aware of the significant impact of anemia on patient quality of life, progression of CKD, and cardiovascular events. Erythropoietin-stimulating agents (ESAs) are associated with significant cardiovascular safety-related concerns, but the emergence of the oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) may improve erythropoiesis without the undesirable downstream effects of ESAs.
Evolving Treatment Paradigms for Bladder Cancer: Expert Perspectives on the Latest Data
  • Hematology
  • Oncology
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Join key thought leaders in the world of bladder cancer – Drs. Sam Chang and Shilpa Gupta – as they review the rapidly evolving bladder cancer treatment landscape across the full continuum of care, from emerging data in NMIBC, to novel neoadjuvant and adjuvant regimens in MIBC, to robust paradigmatic changes in locally advanced and mUC, both in the front-line setting and in subsequent lines of therapy.
New Horizons in Unresectable Stage III NSCLC: A Case-based Exploration of Evolving Data and the Emergence of Immunotherapy
  • Oncology
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Join our Expert Faculty, Drs. Joel W. Neal, MD, PhD and Victoria Sherry, DNP, CRNP, AOCNP as they discuss treatment principles across the continuum of care in unresectable, stage III NSCLC.
New Horizons in Unresectable Stage III NSCLC: A Case-based Exploration of Evolving Data and the Emergence of Immunotherapy
  • Oncology
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Join our Expert Faculty, Drs. Joel W. Neal, MD, PhD and Victoria Sherry, DNP, CRNP, AOCNP as they discuss treatment principles across the continuum of care in unresectable, stage III NSCLC.
Navigating Novel Terrain in Anemia of Chronic Kidney Disease: A Patient-centric Review of Disease State, Current Chasms in Care, and the Future Promise of HIF-PH Inhibition
  • Nephrology
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should be aware of the significant impact of anemia on pat
On Demand: Harnessing the Power of Immunotherapy in HCC and BTC: An Expert Exploration of the Past, Present, and Future of Checkpoint Inhibition
  • Oncology
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
This session will review the totality of emerging evidence for immune checkpoint inhibitors (ICIs) in the hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) management calculus. Faculty will highlight the paradigmatic change ICIs have achieved, emphasize key teaching points for real-world use, and evaluate adaptive clinical trial designs and study schemas being used to investigate ICI-based treatment regimens in HCC and BTC on a prospective basis.
Optimizing Outcomes for Adults with Spinal Muscular Atrophy: Patient-Centric Strategies for the Interprofessional Treatment Team
  • Other
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 IPCE
  • 1.00 Participation
$0.00
Optimizing Outcomes for Adults with Spinal Muscular Atrophy: Patient-Centric Strategies for the Interprofessional Treatment Team
  • Other
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 IPCE
  • 1.00 Participation
$0.00
Digging Deep into the Genome: What Genetic Testing Can (and Can’t) Tell Us about Ovarian Cancer
  • Oncology
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Expert faculty for this 30-minute webinar will include a pathologist and a gynecologic oncologist. Faculty will summarize the latest guidelines on genes that should be tested in ovarian cancer and the appropriate identification of patients who should receive testing. The benefits and limitations of various testing technologies will be discussed (e.g., multigene panel testing), as well as the utility of measuring other indicators of genomic instability (e.g., HRD, LOH, etc.).

Pages